Anti-rituximab antibodies (ARAs) are therapeutic agents developed to recognize and neutralize rituximab, a monoclonal antibody that targets the CD20 antigen found on the surface of pre-B and mature B lymphocytes. These antibodies are used in research and clinical monitoring to evaluate the immunogenicity of rituximab treatment, which may impact therapeutic efficacy and safety. ARAs are particularly relevant in cases where patients exhibit infusion-related reactions, loss of response, or unexpected disease progression despite ongoing therapy.
In the clinical setting, anti-rituximab biomarkers serve as critical tools for therapeutic drug monitoring (TDM), enabling clinicians to measure drug levels and immune responses to optimize patient-specific dosing regimens. Monitoring the presence of ARAs can help identify non-compliance, reduced drug exposure, or increased clearance due to immune complex formation. This information guides treatment adjustments, improves outcomes, and minimizes adverse effects such as infusion reactions or B-cell rebound.
Anti-rituximab biomarkers are especially significant in autoimmune conditions and hematologic malignancies treated with rituximab, where long-term therapy may induce anti-drug antibodies (ADAs). Understanding the immunogenic profile of each patient can inform decisions on therapy continuation, switching to alternative agents, or combining treatments to minimize immune-mediated interference.
This product is manufactured in Turkey by Matriks Biotek.